Brought to you by 
Boehringer teams up with Circuit in psychiatric disorders
04 Sep 2015
Executive Summary
Circuit Therapeutics Inc. agreed to use its optogenetics platform to discover new psychiatric drug targets for Boehringer Ingelheim GMBH. The research collaboration has a three-year term.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boehringer teams up with Circuit in psychiatric disorders
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice